France Vaccine Market Size & Outlook, 2026-2033
- Pharmaceuticals
- Vaccines
- Vaccine Market Outlook
- Vaccines
Global Market
Related Markets
Ask a question about the vaccine market
France vaccine market highlights
- The France vaccine market generated a revenue of USD 2,244.3 million in 2025 and is expected to reach USD 3,784.9 million by 2033.
- The France market is expected to grow at a CAGR of 6.5% from 2026 to 2033.
- In terms of segment, viral vaccines was the largest revenue generating indication in 2025.
- Other Indication is the most lucrative indication segment registering the fastest growth during the forecast period.
Vaccine market data book summary
| Market revenue in 2025 | USD 2,244.3 million |
| Market revenue in 2033 | USD 3,784.9 million |
| Growth rate | 6.5% (CAGR from 2026 to 2033) |
| Largest segment | Viral vaccines |
| Fastest growing segment | Other Indication |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Viral Vaccines, Bacterial Vaccines, Cancer Vaccines, Allergy Vaccines, Other Indication |
| Key market players worldwide | Serum Institute of India Pvt. Ltd., CSL Ltd, Sanofi SA, GSK PLC, Merck & Co Inc, Pfizer Inc, Sinovac Biotech Ltd, BioNTech SE ADR, AstraZeneca PLC, Moderna Inc |
Other key industry trends
- In terms of revenue, France accounted for 3.1% of the global vaccine market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, Germany vaccine market is projected to lead the regional market in terms of revenue in 2033.
- France is the fastest growing regional market in Europe and is projected to reach USD 3,784.9 million by 2033.
In October 2020, France launched a flu vaccine campaign to spread awareness regarding flu and influenza in the country. Such awareness programs help people identify symptoms, thereby creating more demand for influenza vaccines. France has a blend of several regional and multinational players offering influenza vaccines.
Thus, several strategic initiatives undertaken by leading participants are likely to fuel market expansion. For instance, in November 2019, the U.S. FDA approved a supplemental Biologics License Application for Fluzone, a quadrivalent vaccine for adults aged more than 65. Fluzone is a high-dose vaccine containing strains of both influenza A and B.
In addition, increasing approval and development of new vaccines by local key players are anticipated to drive market penetration in other countries, thereby boosting market growth. For instance, in November 2020, Sanofi, a French company, received the European Commission's approval for MenQuadfi for the immunization of children and adults.
No credit card required*
Publish Date: Jul 28, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Vaccine Market Scope
Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| GSK PLC | View profile | 70,200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | www.gsk.com |
| Serum Institute of India Pvt. Ltd. | View profile | 1001-5000 | Pune, Maharashtra, India, Asia | www.seruminstitute.com/ |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Sinovac Biotech Ltd | View profile | 3,261 | No.39, Shangdi Xi Road, Haidan District, Beijing, China, People's Republic of, 100085 | www.sinovac.com |
| CSL Ltd | View profile | 32,000 | 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 | www.csl.com |
| BioNTech SE ADR | View profile | 6,133 | An der Goldgrube 12, Mainz, RP, Germany, D-55131 | www.biontech.de |
| Moderna Inc | View profile | 5,600 | 200 Technology Square, Cambridge, MA, United States, 02139 | www.modernatx.com |
France Vaccine Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Vaccine Market Outlook will help companies and investors design strategic landscapes.
Viral Vaccines was the largest segment with a revenue share of 65.29% in 2025.
Horizon Databook has segmented the France vaccine market based on viral vaccines, bacterial vaccines, cancer vaccines, allergy vaccines, other indication covering the revenue growth of each sub-segment from 2021 to 2033.
In October 2020, France launched a flu vaccine campaign to spread awareness regarding flu and influenza in the country. Such awareness programs help people identify symptoms, thereby creating more demand for influenza vaccines. France has a blend of several regional and multinational players offering influenza vaccines.
Thus, several strategic initiatives undertaken by leading participants are likely to fuel market expansion. For instance, in November 2019, the U.S. FDA approved a supplemental Biologics License Application for Fluzone, a quadrivalent vaccine for adults aged more than 65. Fluzone is a high-dose vaccine containing strains of both influenza A and B.
In addition, increasing approval and development of new vaccines by local key players are anticipated to drive market penetration in other countries, thereby boosting market growth. For instance, in November 2020, Sanofi, a French company, received the European Commission's approval for MenQuadfi for the immunization of children and adults.
- France Vaccine Market Indication Outlook (Revenue, USD Million , 2021-2033)
- Viral Vaccines
- Bacterial Vaccines
- Cancer Vaccines
- Allergy Vaccines
- Other Indication
- France Vaccine Market Type Outlook (Revenue, USD Million , 2021-2033)
- Subunit Vaccines
- Inactivated
- Live Attenuated
- mRNA Vaccines
- Viral Vector Vaccines
- France Vaccine Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Oral
- Parenteral
- Nasal
- France Vaccine Market Age Group Outlook (Revenue, USD Million , 2021-2033)
- Pediatric Age Group
- Adult Age Group
- France Vaccine Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital & Retail Pharmacies
- Government Suppliers
- Others Distribution Channel
Reasons to subscribe to Vaccine Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Vaccine Market Outlook databook
- Our clientele includes a mix of Vaccine Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the France Vaccine Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into France Vaccine Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
France Vaccine Market, 2021-2033 (US$M)
France vaccine market statistics, by indication, 2021-2033 (US$M)
